normative
REMS Plan Could Enable Approval With Oversight
The FDA can ask the sponsor, Lykos, to provide a Risk Evaluation and Mitigation Strategy (REMS) plan establishing guardrails around the advisory committee's concerns; this would enable regulatory approval of MDMA-assisted therapy while continuing to collect adverse-event and safety data in post-approval Phase 4 testing, which is especially valuable because administration will vary more widely once out of the strict Phase 3 protocol.
normativepending
Speaker
Jennifer MitchellEvidence Quote
“that would be a way to enable regulatory approval of mdma-assisted therapy and ensure that data were still being collected to look at adverse events side effects etc in what we'd call phase 4 testing”
Created: 6/14/2026, 2:01:41 AM
Your notes
Loading notes...